Skip to content

Reproductive Outcome in Assisted Conception Cycles

Prediction Of Reproductive Outcome in Assisted Conception Cycles in Women With Unexplained Infertility

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03846388
Enrollment
292
Registered
2019-02-19
Start date
2019-02-01
Completion date
2022-01-31
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Infertility is the failure to conceive after regular unprotected sexual intercourse for one year. Primary infertility refers woman who has never conceived, and secondary infertility to one who has had a previous pregnancy.The most frequent causes for infertility are ovulatory disorder or anovulation (27-30%) , tubal factor(20-22%), abnormal semen parameters(45-50%). Unexplained infertility refers to infertile couples in whom standard investigations, including tests of ovulation, tubal patency tests and semen analysis are normal. incidence 15-17% of infertile couples. New guidelines on infertility recommend that women with unexplained infertility should be advised for expectant management for 2 years .If pregnancy is not achieved after this period In vitro fertilization Should be considered. The Fast Track and Standard Treatment trial demonstrated A shorter time to pregnancy and higher per cycle pregnancy rates for In vitro fertilization compared with treatment with oral agents or gonadotropins in Patients with unexplained infertility. Successful pregnancy after assisted reproductive technology is influenced by numerous predictors that have been investigated in the previous years. The central predictors of success are the sperm, oocyte quality and endometrial receptivity. Oocyte quality depends mainly on the age of the woman , and her ovarian reserve. Parameters most commonly studied are the woman's age , her antral follicle count , and laboratory tests including serum randomly done during the menstrual cycle levels at day 3 of the cycle.

Interventions

DIAGNOSTIC_TESTfollicular stimulating hormone

in the serum of our patients

DIAGNOSTIC_TESTAnti-mullerian hormone

in the serum of our patients

RADIATIONBasal antral follicle count

by ultrasound

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* in vitro fertilization treatment due to many factors including tubal, male, and unexplained factors. * body mass index (BMI) (18-35)kg/m2

Exclusion criteria

1. patient age less than 20 and more than 40 years. 2. body mass index less than 18 and more than 35 kg/m2. 3. period of infertility less than 2 years.. 4. untreated hyperthyroidism, hypothyroidism, diabetes, hypertension.

Design outcomes

Primary

MeasureTime frame
live birth rate12 months

Secondary

MeasureTime frame
Number of fertilized oocytes3 days

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026